Skip to main content
. 2015 Apr 4;6(6):692–698. doi: 10.1111/jdi.12346

Figure 1.

Figure 1

(a) Adjusted mean change in glycated hemoglobin (HbA1c) from baseline at week 24 with linagliptin or placebo as monotherapy (full analysis set – last observation carried forward). (b) Adjusted mean change from baseline in HbA1c over time (full analysis set – last observation carried forward). Model includes treatment, baseline HbA1c and previous antidiabetes medication.